RXRX (Recursion Pharmaceuticals) Long-Term Debt: $4.75 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RXRX Recursion Pharmaceuticals Inc RXRX
66 GF Score
Price $3.50
GF Value $3.02
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Recursion Pharmaceuticals Long-Term Debt?

Recursion Pharmaceuticals RXRX +4.95% 66 Long-Term Debt is $4.75 Mil as of Jun. 2026. GuruFocus rates RXRX with a GF Score™ of 66/100 and a GF Value™ of $3.02 (Modestly Overvalued). The stock has 4 warning signs investors should review.

Recursion Pharmaceuticals's Long-Term Debt for the quarter that ended in Jun. 2026 was $4.75 Mil.

Recursion Pharmaceuticals's quarterly Long-Term Debt declined from Dec. 2025 ($9.56 Mil) to Mar. 2026 ($7.18 Mil) and declined from Mar. 2026 ($7.18 Mil) to Jun. 2026 ($4.75 Mil).

Recursion Pharmaceuticals's annual Long-Term Debt increased from Dec. 2023 ($1.10 Mil) to Dec. 2024 ($19.02 Mil) but then declined from Dec. 2024 ($19.02 Mil) to Dec. 2025 ($9.56 Mil).

Recursion Pharmaceuticals  (NAS:RXRX) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Recursion Pharmaceuticals Long-Term Debt Related Terms

Recursion Pharmaceuticals Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Recursion Pharmaceuticals's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Recursion Pharmaceuticals Long-Term Debt Chart

Recursion Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial 0.63 0.54 1.10 19.02 9.56

Recursion Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.20 11.90 9.56 7.18 4.75
RXRX
66GF Score
Recursion Pharmaceuticals Inc RXRX
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $4.75 Mil mean?
Recursion Pharmaceuticals (RXRX) has a Long-Term Debt of $4.75 Mil as of Jun. 2026.
Is Recursion Pharmaceuticals' Long-Term Debt too high?
Recursion Pharmaceuticals' current Long-Term Debt is $4.75 Mil. Overall, Recursion Pharmaceuticals has a GF Score™ of 66/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Recursion Pharmaceuticals' Long-Term Debt compare to INVA and TSHA?
Recursion Pharmaceuticals' Long-Term Debt of $4.75 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Recursion Pharmaceuticals's current Long-Term Debt is $4.75 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Recursion Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Recursion Pharmaceuticals (RXRX) is currently considered Modestly Overvalued. The stock's GF Value™ is $3.02, compared to a current price of $3.50 — trading 15.7% above its estimated fair value. The current Long-Term Debt is $4.75 Mil. Recursion Pharmaceuticals' overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Recursion Pharmaceuticals (RXRX), the current Long-Term Debt is $4.75 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Recursion Pharmaceuticals (RXRX) Overvalued in 2026?

Based on GuruFocus' analysis, Recursion Pharmaceuticals stock appears to be overvalued. The current stock price of $3.50 is trading 15.7% above its estimated GF Value™ of $3.02. GuruFocus considers Recursion Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for RXRX:

  • Long-Term Debt: $4.75 Mil
  • GF Value™: $3.02 vs. price of $3.50 (15.7% above fair value)
  • GF Score™: 66/100 with 4 warning signs

No single metric tells the full story. See the RXRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Recursion Pharmaceuticals Business Description

Other Exchanges RXRX:Mexico
Address 41 South Rio Grande Street, Salt Lake City, UT, USA, 84101
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.
66GF Score

Get the complete analysis for RXRX

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.50
Price
$3.02
GF Value